These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1812674)

  • 1. [Effectiveness and tolerance of the selective MAO-A inhibitor moclobemide in children with hyperkinetic syndrome].
    Trott GE; Menzel M; Friese HJ; Nissen G
    Z Kinder Jugendpsychiatr; 1991 Dec; 19(4):248-53. PubMed ID: 1812674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of moclobemide in children with attention deficit hyperactivity disorder.
    Trott GE; Friese HJ; Menzel M; Nissen G
    Psychopharmacology (Berl); 1992; 106 Suppl():S134-6. PubMed ID: 1546129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Administration of moclobemide++ in children with attention deficit hyperactivity disorder ].
    Antkowiak R; Rajewski A
    Psychiatr Pol; 1998; 32(6):751-7. PubMed ID: 10216387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies of selective and reversible monoamine oxidase inhibitors.
    Mann JJ; Aarons SF; Frances AJ; Brown RD
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):62-6. PubMed ID: 6429130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.
    Nair NP; Ahmed SK; Kin NM
    J Psychiatry Neurosci; 1993 Nov; 18(5):214-25. PubMed ID: 7905288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled double-blind trial of moclobemide and imipramine in the treatment of depression.
    Kok LP; Tsoi WF
    Singapore Med J; 1995 Feb; 36(1):38-40. PubMed ID: 7570133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with moclobemide and methylphenidate for comorbid major depression and adult attention-deficit/hyperactivity disorder.
    Myronuk LD; Weiss M; Cotter L
    J Clin Psychopharmacol; 1996 Dec; 16(6):468-9. PubMed ID: 8959481
    [No Abstract]   [Full Text] [Related]  

  • 10. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease.
    Ruggieri S; Fabbrini G; Bramante L; DePandis F; Stocchi F; Barbanti P; Vacca L; Manfredi M
    Adv Neurol; 1996; 69():595-8. PubMed ID: 8615185
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Preventive treatment of migraine and chronic tension headache with moclobemide].
    Meienberg O; Amsler F
    Praxis (Bern 1994); 1997 Jul; 86(27-28):1107-12. PubMed ID: 9324719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of benzamide derivatives on convulsions induced by the toxic action of oxygen in rats].
    Gol'dina OA; Tepliakov VG; Demurov EA; Koloskov IuB; Zagorevskiĭ VA
    Biull Eksp Biol Med; 1987 Oct; 104(10):469-71. PubMed ID: 3676473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide, imipramine, and placebo in the treatment of major depression (DSM III).
    Versiani M; Nardi AE; Mundim FD; Alves AB
    J Neural Transm Suppl; 1989; 28():65-75. PubMed ID: 2794994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M; Keller HH; Kettler R
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders.
    Priest RG; Gimbrett R; Roberts M; Steinert J
    Acta Psychiatr Scand Suppl; 1995; 386():40-3. PubMed ID: 7717094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.
    Berlin I; Saïd S; Spreux-Varoquaux O; Launay JM; Olivares R; Millet V; Lecrubier Y; Puech AJ
    Clin Pharmacol Ther; 1995 Oct; 58(4):444-52. PubMed ID: 7586937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of reversible MAO-A inhibitors.
    Bieck PR; Antonin KH; Schmidt E
    Clin Neuropharmacol; 1992; 15 Suppl 1 Pt A():345A-346A. PubMed ID: 1498864
    [No Abstract]   [Full Text] [Related]  

  • 19. Antidepressant effect of Ro 11-1163, a new MAO inhibitor.
    Stefanis CN; Alevizos BH; Papadimitriou GN
    Int Pharmacopsychiatry; 1982; 17(1):43-8. PubMed ID: 7045018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled trial of moclobemide in social phobia.
    Schneier FR; Goetz D; Campeas R; Fallon B; Marshall R; Liebowitz MR
    Br J Psychiatry; 1998 Jan; 172():70-7. PubMed ID: 9534836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.